BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34077738)

  • 1. C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma.
    Yang M; Su Y; Wang Z; Du D; Wei S; Liao Z; Zhang Q; Zhao L; Zhang X; Han L; Jiang J; Zhan M; Sun L; Yuan S; Zhou Z
    Biochem Pharmacol; 2021 Aug; 190():114641. PubMed ID: 34077738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Pharmacokinetics of C118P, a Novel Prodrug of Microtubules Inhibitor and Its Metabolite C118 in Mice, Rats, and Dogs.
    Zhang C; Zhang X; Wang G; Peng Y; Zhang X; Wu H; Yu B; Sun J
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30400617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
    J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
    Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
    Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MIL-1, a novel antitumor agent derived from natural product millepachine, acts as tubulin polymerization inhibitor for the treatment of hepatocellular carcinoma.
    Yan J; Zhuang Q; Li Z; Xiong Y; He M; Kang C; Zhang Q; Han L; Liang E; Liu H; Ke P; Huang X
    Eur J Pharmacol; 2021 May; 898():173975. PubMed ID: 33647258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
    Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Novel Nature Microtubule Inhibitor Ivalin Induces G2/M Arrest and Apoptosis in Human Hepatocellular Carcinoma SMMC-7721 Cells In Vitro.
    Liu F; Lin S; Zhang C; Ma J; Han Z; Jia F; Xie W; Li X
    Medicina (Kaunas); 2019 Aug; 55(8):. PubMed ID: 31409007
    [No Abstract]   [Full Text] [Related]  

  • 9. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
    Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
    Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
    Ren X; Dai M; Lin LP; Li PK; Ding J
    Br J Pharmacol; 2009 Apr; 156(8):1228-38. PubMed ID: 19302593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
    Yang C; Qin S
    Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin.
    Peng T; Wu JR; Tong LJ; Li MY; Chen F; Leng YX; Qu R; Han K; Su Y; Chen Y; Duan WH; Xie H; Ding J
    Acta Pharmacol Sin; 2014 Jul; 35(7):916-28. PubMed ID: 24858311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azaindole derivatives are inhibitors of microtubule dynamics, with anti-cancer and anti-angiogenic activities.
    Prudent R; Vassal-Stermann É; Nguyen CH; Mollaret M; Viallet J; Desroches-Castan A; Martinez A; Barette C; Pillet C; Valdameri G; Soleilhac E; Di Pietro A; Feige JJ; Billaud M; Florent JC; Lafanechère L
    Br J Pharmacol; 2013 Feb; 168(3):673-85. PubMed ID: 23004938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
    Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
    Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.
    Moser C; Lang SA; Mori A; Hellerbrand C; Schlitt HJ; Geissler EK; Fogler WE; Stoeltzing O
    BMC Cancer; 2008 Jul; 8():206. PubMed ID: 18651980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain.
    Li W; Yin Y; Shuai W; Xu F; Yao H; Liu J; Cheng K; Xu J; Zhu Z; Xu S
    Bioorg Chem; 2019 Mar; 83():380-390. PubMed ID: 30408650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
    Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
    Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site.
    Boichuk S; Galembikova A; Syuzov K; Dunaev P; Bikinieva F; Aukhadieva A; Zykova S; Igidov N; Gankova K; Novikova M; Kopnin P
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C118P exerted potent anti-tumor effects against melanoma with induction of G2/M arrest via inhibiting the expression of BUB1B.
    Ren K; Zhou M; Li L; Wang C; Yuan S; Li H
    J Dermatol Sci; 2022 Nov; 108(2):58-67. PubMed ID: 36424293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
    Moon CH; Lee SJ; Lee HY; Dung le TK; Cho WJ; Cha H; Park JW; Min YJ
    Invest New Drugs; 2014 Jun; 32(3):400-11. PubMed ID: 24202729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.